Clinical trials for Pleural mesothelioma
63 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD · PI: David Bartlett, MD
- RECRUITINGN/ANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago · PI: Darren Bryan, MD
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPhase 1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI) · PI: Raffit Hassan, M.D.
- RECRUITINGPhase 2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPhase 2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University · PI: Ma
- RECRUITINGPhase 2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital · PI: Helle Zacho, MD, DMSc
- RECRUITINGPhase 1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited
- RECRUITINGPhase 2NCT05647265Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaAlliance for Clinical Trials in Oncology
- RECRUITINGN/ANCT06910449Hemithoracic Arc Radiotherapy Post Pleural DecorticationCairo University
- ACTIVE NOT RECRUITINGPhase 2NCT06155279Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)Istituto Oncologico Veneto IRCCS · PI: Giulia Pasello, MD
- RECRUITINGPhase 2NCT05188859First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Wang, MD,PhD
- RECRUITINGPhase 2NCT06535607Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsAstraZeneca
- RECRUITINGPhase 1NCT06251310SW-682 in Advanced Solid TumorsSpringWorks Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT05932199Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for MesotheliomaBaylor College of Medicine · PI: Robert Ripley, MD
- RECRUITINGPhase 2NCT06477419A Study of Sacituzumab Govitecan in People With MesotheliomaMemorial Sloan Kettering Cancer Center · PI: Michael Offin, MD
- RECRUITINGPhase 1NCT06726564A Study of MT027 in Patients with Pleural Malignant TumorsSuzhou Maximum Bio-tech Co., Ltd.
- RECRUITINGN/ANCT06451536Ga-68 FAPI PET Before ImmunotherapyAnkara University
- RECRUITINGN/ANCT06410625Evaluation of Response by FLT PET in MesotheliomaAnkara University
- RECRUITINGN/ANCT05655078Hemithoracic Irradiation With Proton Therapy in Malignant Pleural MesotheliomaUniversity College, London · PI: Crispin Hiley
- RECRUITINGNCT06637345Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)Centro di Riferimento Oncologico - Aviano · PI: Alberto Revelant, MD
- RECRUITINGPhase 2NCT06318286Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaHyogo Medical University · PI: Kozo Kuribayashi, MD, PhD
- RECRUITINGN/ANCT06538376Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICUBrigham and Women's Hospital · PI: Gyorgy Frendl, MD PhD
- RECRUITINGNCT05628376TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVOUniversity College, London
- RECRUITINGPhase 3NCT06097728MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaAstraZeneca · PI: Marjorie G Zauderer, MD
- RECRUITINGPhase 2NCT05930665Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural MesotheliomaSun Yat-sen University
- RECRUITINGN/ANCT06037941Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural MesotheliomaMemorial Sloan Kettering Cancer Center · PI: Gaetano Rocco, MD
- RECRUITINGNCT05538806TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma StudyNovoCure Ltd.
- RECRUITINGNCT06031636Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural MesotheliomaTianjin Medical University Second Hospital
- RECRUITINGNCT06886672Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE VariaTionSFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGN/ANCT06946498First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.National and Kapodistrian University of Athens · PI: Grigorios Stratakos, Professor
- RECRUITINGPHASE1, PHASE2NCT05765084Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural MesotheliomaUniversity Hospital, Antwerp · PI: Zwi N Berneman, MD, PhD
- RECRUITINGPhase 1NCT03760575Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)Abramson Cancer Center at Penn Medicine · PI: Corey Langer, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05451849A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerTCR2 Therapeutics
- RECRUITINGPhase 1NCT05245500Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionBristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGPhase 2NCT04400539The IMmunotherapy Pleural 5-ALA PDTUniversity Hospital, Lille · PI: Arnaud Scherpereel, MD,PhD
- RECRUITINGPhase 3NCT04996017Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)Gruppo Oncologico Italiano di Ricerca Clinica
- ACTIVE NOT RECRUITINGPhase 1NCT04897022A Study of Pembrolizumab and Radiation Therapy in People With MesotheliomaMemorial Sloan Kettering Cancer Center · PI: Charles Simone, MD
- ACTIVE NOT RECRUITINGPhase 1NCT04926948Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of MesotheliomaMayo Clinic · PI: William G. Breen, M.D.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04913337Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, Inc · PI: Chief Medical Officer
- ACTIVE NOT RECRUITINGPhase 2NCT04287829Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsThe Netherlands Cancer Institute · PI: S Burgers, PhD
- RECRUITINGPhase 2NCT04515836Olaparib in Patients With HRD Malignant MesotheliomaUniversity of Chicago · PI: Hedy L Kindler, MD
- ACTIVE NOT RECRUITINGPhase 1NCT04577326Mesothelin-targeted CAR T-cell Therapy in Patients With MesotheliomaMemorial Sloan Kettering Cancer Center · PI: Roisin O'Cearbhaill, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04300244Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaÅslaug Helland · PI: Åslaug Helland, Prof, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03546426Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior TherapiesIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · PI: Massimo Guidoboni, MD
- ACTIVE NOT RECRUITINGPhase 1NCT04162015A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaMemorial Sloan Kettering Cancer Center · PI: Michael Offin, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03918252Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · PI: Julie Brahmer, MD
- ACTIVE NOT RECRUITINGN/ANCT04028570A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural ResectionUniversity Health Network, Toronto · PI: John Cho, MD, PhD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03907852Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerTCR2 Therapeutics
- ACTIVE NOT RECRUITINGPhase 3NCT03710876Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural MesotheliomaFerring Ventures Limited · PI: Daniel Sterman, MD
- RECRUITINGN/ANCT03683680Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic BiomarkersDana-Farber Cancer Institute · PI: Raphael Bueno, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03126630Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaNational Cancer Institute (NCI) · PI: Aaron S Mansfield
- ACTIVE NOT RECRUITINGPhase 1NCT03228537Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaNational Cancer Institute (NCI) · PI: Anne S Tsao
- ACTIVE NOT RECRUITINGN/ANCT03269227Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural MesotheliomaIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · PI: Elisabetta Parisi, MD
- ACTIVE NOT RECRUITINGPhase 1NCT02959463Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant MesotheliomaM.D. Anderson Cancer Center · PI: Matthew Ning, MD, MPH
- RECRUITINGPhase 2NCT03007030Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryM.D. Anderson Cancer Center · PI: Anne S Tsao
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02414269Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinMemorial Sloan Kettering Cancer Center · PI: Roisin O'Cearbhaill, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02399371Pembrolizumab in Treating Patients With Malignant MesotheliomaUniversity of Chicago · PI: Hedy Kindler
- ACTIVE NOT RECRUITINGPhase 2NCT02153229Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural MesotheliomaAbramson Cancer Center at Penn Medicine · PI: Keith Cengel, MD, PhD
- RECRUITINGNCT01851395Rapid Autopsy and Procurement of Cancer TissueNational Cancer Institute (NCI) · PI: Anish Thomas, M.D.
- RECRUITINGNCT01950572Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaNational Cancer Institute (NCI) · PI: Raffit Hassan, M.D.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01064648Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaNational Cancer Institute (NCI) · PI: Anne S Tsao
- ACTIVE NOT RECRUITINGPhase 2NCT00715611Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural MesotheliomaMemorial Sloan Kettering Cancer Center · PI: Charles Simone, MD